Download PDF
Zentralbl Chir 2003; 128(11): 906-910
DOI: 10.1055/s-2003-44797
Originalarbeiten und Übersichten

© Georg Thieme Verlag Stuttgart · New York

Medikamentöse Therapie des hepatozellulären Karzinoms

Systemic Treatment for Hepatocellular CarcinomaH. C. Spangenberg1 , I. Zuber-Jerger1 , R. Thimme1 , H. E. Blum1 , F. von Weizsäcker1
  • 1Abteilung Innere Medizin II, Medizinische Universitätsklinik Albert-Ludwigs-Universität Freiburg(Ärztlicher Direktor: Prof. Dr. Drs. h. c. H. E. Blum)
Further Information

Publication History

Publication Date:
11 December 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das hepatozelluläre Karzinom (HCC) ist einer der häufigsten malignen Tumoren weltweit. Für die medikamentöse Therapie des HCC wurden bzw. werden verschiedene Strategien evaluiert: konventionelle Chemotherapie, Tamoxifen, Octreotid, Thymostimulin bzw. α1-Thymophysin, Pravastatin, 131J-Lipiodol sowie die transarterielle Chemoperfusion (TAC) bzw. Chemoembolisation (TACE). Lediglich für die TACE (als Monotherapie oder kombiniert mit Pravastatin) ließ sich bisher ein Überlebensvorteil bei selektionierten Patienten nachweisen. Neue, viel versprechende Therapiestrategien wie Immun- bzw. Gentherapie, Antiangiogenese und Cyclooxygenaseinhibition werden zur Zeit in präklinischen und klinischen Studien evaluiert. Für die Primärprävention des HCC existieren wirksame Strategien und auch in der Sekundärprävention sind erste Erfolge berichtet worden.

Abstract

Hepatocellular carcinoma (HCC) is one of the most frequent malignancies worldwide. A variety of pharmacological strategies has been evaluated in the treatment of HCC: classical chemotherapy, tamoxifen, octreotide, thymostimulin, pravastatin, 131I-lipiodol as well as transarterial chemoperfusion (TAC) and chemoembolisation (TACE). TACE monotherapy or TACE combined with pravastatin resulted in a survival benefit of selected HCC patients. New strategies such as immunotherapy, antiangiogenic agents or cyclooxygenase inhibitors are under clinical investigation and might play a role in future therapies for HCC. Efficient strategies for the primary prevention of HCC are available and promising concepts in the secondary prevention have been reported.

Schlüsselwörter

Hepatozelluläres Karzinom - medikamentöse Therapie - transarterielle Chemoembolisation - Antihormontherapie

Key words

Hepatocellular carcinoma - systemic therapy - transarterial chemoembolisation - tamoxifen - octreotide

Literatur

  • 1 Allgaier H P. Das hepatozelluläre Karzinom. UNI-MED, Bremen 2002
    Google Scholar
  • 2 Biederer C, Ries S, Brandts C H, McCormick F. Replication-selective viruses for cancer therapy.  J Mol Med. 2002;  80 163-175
    CrossrefPubMedGoogle Scholar
  • 3 Block A, Chen S H, Kosai K, Finegold M, Woo S L. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors.  Pancreas. 1997;  15 25-34
    PubMedGoogle Scholar
  • 4 Blum H E, Linhart H. Gene therapy for hepatocellular carcinoma.  Viral Hepatitis. 1999;  5 147-157
    PubMedGoogle Scholar
  • 5 Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxi A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.  Radiology. 2002;  224 47-54
    CrossrefPubMedGoogle Scholar
  • 6 Cantz T, Ott M, Kubicka S, Manns M P. Gen- und Immuntherapie von Lebererkrankungen.  Internist. 2001;  42 1357-1365
    CrossrefPubMedGoogle Scholar
  • 7 Carmeliet P, Jain R K. Angiogenesis in cancer and other diseases.  Nature. 2000;  407 249-257
    CrossrefPubMedGoogle Scholar
  • 8 Caruso M, Panis Y, Gagandeep S, Houssin D, Salzman J L, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene.  Proc Natl Acad Sci USA. 1993;  90 7024-7028
    PubMedGoogle Scholar
  • 9 Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, Vilana R, Rodes J. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients.  Gastroenterology. 1995;  109 917-922
    CrossrefPubMedGoogle Scholar
  • 10 Chan E S, Chow P K, Tai B C, Machin D, Sook C. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Update Software. The Cochrane Library, Oxford 2002; 4
    Google Scholar
  • 11 Chen C J, Yu M W, Liaw Y F. Epidemiological characteristics and risk factors of hepatocellular carcinoma.  J Gastroenterol Hepatol. 1997;  12 294-308
    PubMedGoogle Scholar
  • 12 Cheng A L, Yeh K H, Fine R L, Chuang S E, Yang C H, Wang L H, Chen D S. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.  Hepatogastroenterology. 1998;  45 1955-1960
    PubMedGoogle Scholar
  • 13 Chenivesse X, Franco D, Brechot C. MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis.  J Hepatol. 1993;  18 168-172
    CrossrefPubMedGoogle Scholar
  • 14 Chow P K, Tai B C, Tan C K, Machin D, Win K M, Johnson P J, Soo K C. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial.  Hepatology. 2002;  36 1221-1226
    CrossrefPubMedGoogle Scholar
  • 15 CLIP Group (Cancer of the Liver Italian Programme) . Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial.  Lancet. 1998;  352 17-20
    CrossrefPubMedGoogle Scholar
  • 16 Deuffic S, Buffat L, Poynard T, Valleron A J. Modeling the hepatitis C virus epidemic in France.  Hepatology. 1999;  29 1596-1601
    CrossrefPubMedGoogle Scholar
  • 17 Elba S, Giannuzzi V, Misciagna G, Manghisi O G. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma.  Ital J Gastroenterol. 1994;  26 66-68
    PubMedGoogle Scholar
  • 18 El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States.  N Engl J Med. 1999;  340 745-750
    CrossrefPubMedGoogle Scholar
  • 19 Engstrom P F, Levin B, Moertel C G, Schutt A. A phase II trial of tamoxifen in hepatocellular carcinoma.  Cancer. 1990;  65 2641-2643
    CrossrefPubMedGoogle Scholar
  • 20 Farinati F, Salvagnini M, de Maria N, Fornasiero A, Chiaramonte M, Rossaro L, Naccarato R. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen.  J Hepatol. 1990;  11 297-301
    CrossrefPubMedGoogle Scholar
  • 21 Friedl J, Stift A, Paolini P, Roth E, Steger G G, Mader R, Jakesz R, Gnant M F. Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer.  Cancer Biother Radiopharm. 2000;  15 477-486
    PubMedGoogle Scholar
  • 22 Fuchs C S, Clark J W, Ryan D P, Kulke M H, Kim H, Earle C C, Vincitore M, Mayer R J, Stuart K E. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.  Cancer. 2002;  94 3186-3191
    CrossrefPubMedGoogle Scholar
  • 23 Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor. A prospective randomized study of hepatitis C virus-related liver cancer.  Hepatology. 2000;  32 228-232
    CrossrefPubMedGoogle Scholar
  • 24 Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.  Br J Cancer. 2001;  84 886-891
    CrossrefPubMedGoogle Scholar
  • 25 Khuri F R, Nemunaitis J, Ganly I, Arseneau J, Tannock I F, Romel L, Gore M, Ironside J, MacDougall R H, Heise C, Randlev B, Gillenwater A M, Bruso P, Kaye S B, Hong W K, Kirn D H. A controlled trial of intratumoral Onyx-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.  Nat Med. 2000;  6 879-885
    CrossrefPubMedGoogle Scholar
  • 26 Kin M, Torimura T, Ueno T, Nakamura T, Ogata R, Sakamoto M, Tamaki S, Sata M. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats.  Int J Oncol. 2000;  16 375-382
    PubMedGoogle Scholar
  • 27 Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos O N. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.  Gut. 1998;  42 442-447
    CrossrefPubMedGoogle Scholar
  • 28 Kubicka S, Rudolph K L, Tietze M K, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.  Hepatogastroenterology. 2001;  48 783-789
    PubMedGoogle Scholar
  • 29 Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, Strong R, Leggett B, Powell L, Maddern G, Ellem K, Cooksley G. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells.  J Gastroenterol Hepatol. 2002;  17 889-896
    CrossrefPubMedGoogle Scholar
  • 30 Lau W Y, Leung T W, Ho S K, Chan M, Machin D, Lau J, Chan A T, Yeo W, Mok T S, Yu S C, Leung N W, Johnson P J. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.  Lancet. 1999;  353 797-801
    CrossrefPubMedGoogle Scholar
  • 31 Lin D Y, Lin S M, Liaw Y F. Non-surgical treatment of hepatocellular carcinoma.  J Gastroenterol Hepatol. 1997;  12 319-328
    PubMedGoogle Scholar
  • 32 Lisker-Melman M, Martin P, Hoofnagle J H. Conditions associated with hepatocellular carcinoma.  Med Clin North Am. 1989;  73 999-1009
    PubMedGoogle Scholar
  • 33 Llovet J M, Real M I, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.  Lancet. 2002;  359 1734-1739
    CrossrefPubMedGoogle Scholar
  • 34 Lo C M, Ngan H, Tso W K, Liu C L, Lam C M, Poon R T, Fan S T, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.  Hepatology. 2002;  35 1164-1171
    CrossrefPubMedGoogle Scholar
  • 35 Lozano R D, Patt T Z, Hassan M M. Oral capecatibine for the treatment of hepatobiliary cancers.  Proc Am Soc Clin Oncol. 2000;  19 264
    PubMedGoogle Scholar
  • 36 Martinez Cerezo F J, Tomas A, Donoso L, Enriquez J, Guarner C, Balanzo J, Martinez Nogueras A, Vilardell F. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma.  J Hepatol. 1994;  20 702-706
    CrossrefPubMedGoogle Scholar
  • 37 Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin M F, Khayat D, Opolon P, Poynard T. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis?.  Aliment Pharmacol Ther. 1998;  12 111-126
    CrossrefPubMedGoogle Scholar
  • 38 Murray C J, Lopez A D. Mortality by cause for eight regions of the world: Global Burden of Disease Study.  Lancet. 1997;  349 1269-1276
    CrossrefPubMedGoogle Scholar
  • 39 Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki K T, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group.  N Engl J Med. 1996;  334 1561-1567
    CrossrefPubMedGoogle Scholar
  • 40 Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma.  N Engl J Med. 1999;  340 1046-1047
    CrossrefPubMedGoogle Scholar
  • 41 Neuhaus P, Jonas S. Lebertransplantation beim hepatozellulären Karzinom: neue Entwicklungen.  Schweiz Rundsch Med Prax. 2002;  91 1396-1400
    PubMedGoogle Scholar
  • 42 Palmieri G, Biondi E, Morabito A, Rea A, Gravina A, Bianco A R. Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis.  Int J Canc. 1996;  8 827-832
    PubMedGoogle Scholar
  • 43 Patt Y Z, Hassan M M, Lozano R D, Ellis L M, Peterson J A, Waugh K A. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide.  Am J Clin Oncol. 2000;  23 319-321
    PubMedGoogle Scholar
  • 44 Patt Y Z, Hassan M M, Lozano R D, Waugh K A, Hoque A M, Frome A I, Lahoti S, Ellis L, Vauthey J N, Curley S A, Schnirer I I, Raijman I. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.  Clin Cancer Res. 2001;  7 3375-3380
    PubMedGoogle Scholar
  • 45 Perrone F, Gallo C, Daniele B, Gaeta G B, Izzo F, Capuano G, Adinolfi L E, Mazzanti R, Farinati F, Elba S, Piai G, Calandra M, Stanzione M, Mattera D, Aiello A, De Sio I, Castiglione F, Russo M, Persico M, Felder M, Manghisi O G, De Maio E, Di Maio M, Pignata S. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial.  Curr Pharm Des. 2002;  8 1013-1019
    PubMedGoogle Scholar
  • 46 Rabe C, Pilz T, Allgaier H P, Halm U, Strasser C, Wettstein M, Sauerbruch T, Caselmann W H. Klinische Resultate einer Octreotidbehandlung bei 63 Patienten mit hepatozellulärem Karzinom.  Z Gastroenterol. 2002;  40 395-400
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Reubi J C, Zimmermann A, Jonas S, Waser B, Neuhaus P, Laderach U, Wiedenmann B. Regulatory peptide receptors in human hepatocellular carcinomas.  Gut. 1999;  45 766-774
    PubMedGoogle Scholar
  • 48 Riestra S, Rodriguez M, Delgado M, Suarez A, Gonzalez N, de la Mata M, Diaz G, Mino-Fugarolas G, Rodrigo L. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma.  J Clin Gastroenterol. 1998;  26 200-203
    PubMedGoogle Scholar
  • 49 Schachschal G, Lochs H, Plauth M. Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma.  Eur J Gastroenterol Hepatol. 2000;  12 281-284
    PubMedGoogle Scholar
  • 50 Schwartz J D, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.  Lancet Oncol. 2002;  3 593-603
    CrossrefPubMedGoogle Scholar
  • 51 Simonetti R G, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials.  Ann Oncol. 1997;  8 117-136
    CrossrefPubMedGoogle Scholar
  • 52 Soini Y, Virkajarvi N, Raunio H, Paakko P. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.  J Clin Pathol. 1996;  49 470-473
    PubMedGoogle Scholar
  • 53 Stefanini G F, Foschi F G, Castelli E, Marsigli L, Biselli M, Mucci F, Bernardi M, Van Thiel D H, Gasbarrini G. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience.  Hepatogastroenterology. 1998;  45 209-215
    PubMedGoogle Scholar
  • 54 Takahashi M, Sato T, Sagawa T, Lu Y, Sato Y, Iyama S, Yamada Y, Fukaura J, Takahashi S, Miyanishi K, Yamashita T, Sasaki K, Kogawa K, Hamada H, Kato J, Niitsu Y. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor.  Mol Ther. 2002;  5 627-634
    CrossrefPubMedGoogle Scholar
  • 55 Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.  Lancet. 2000;  356 802-807
    CrossrefPubMedGoogle Scholar
  • 56 Urbich C, Dernbach E, Zeiher A M, Dimmeler S. Double-edged role of statins in angiogenesis signaling.  Circ Res. 2002;  90 737-744
    CrossrefPubMedGoogle Scholar
  • 57 Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, De Santis M, Manenti F. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival.  Hepatology. 2000;  32 233-238
    CrossrefPubMedGoogle Scholar
  • 58 Villa E, Grottola A, Buttafaco P, Buono M G, Giannini F, Manno M, Bertani H, Dugani A, Manenti F. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors.  Br J Cancer. 2001;  85 1606-1608
    PubMedGoogle Scholar
  • 59 Vincent L, Soria C, Mirshahi F, Opolon P, Mishal Z, Vannier J P, Soria J, Hong L. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models.  Arterioscler Thromb Vasc Biol. 2002;  22 623-629
    PubMedGoogle Scholar
  • 60 von Weizsacker F, Allgaier H P, Blum H E. Prävention des hepatozellulären Karzinoms.  Schweiz Rundsch Med Prax. 2002;  91 1393-1395
    PubMedGoogle Scholar
  • 61 Weis M, Heeschen C, Glassford A J, Cooke J P. Statins have biphasic effects on angiogenesis.  Circulation. 2002;  105 739-745
    CrossrefPubMedGoogle Scholar
  • 62 Yang T S, Lin Y C, Chen J S, Wan H M, Wang C H. Phase-II-study of gemcitabine in patients with advanced hepatocellular carcinoma.  Cancer. 2000;  89 750-756
    CrossrefPubMedGoogle Scholar
  • 63 Yang T S, Wang C H, Hsieh R K, Chen J S, Fung M C. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial.  Ann Oncol. 2002;  13 1771-1778
    CrossrefPubMedGoogle Scholar
  • 64 Yuen M F, Poon R T, Lai C L, Fan S T, Lo C M, Wong K W, Wong W M, Wong B C. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.  Hepatology. 2002;  36 687-691
    CrossrefPubMedGoogle Scholar

Prof. Dr. F. von Weizsäcker

Abteilung Innere Medizin II

Medizinische Universitätsklinik

Albert-Ludwigs-Universität Freiburg

Hugstetter Straße 55

79106 Freiburg

Email: weiz@ukl.uni-freiburg.de